ENTREMED, INC. (NASDAQ:ENMD)

CAPS Rating: No stars

A clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them.

Results 1 - 15 of 15

Recs

0
Member Avatar Allstar13913 (99.80) Submitted: 3/6/2012 2:47:00 AM : Underperform Start Price: $2.02 ENMD Score: +42.22

Biopharma Failure going back to 1998. Has never had any success.

http://www.cnbc.com/id/46300316

Recs

0
Member Avatar jesusbmine (20.04) Submitted: 11/27/2010 6:15:48 PM : Outperform Start Price: $5.99 ENMD Score: -126.07

yes

Recs

0
Member Avatar denaliguy (< 20) Submitted: 10/18/2010 4:19:43 PM : Outperform Start Price: $3.79 ENMD Score: -109.71

Watch for thid in China

Recs

0
Member Avatar amteague777 (94.82) Submitted: 6/1/2007 6:27:37 PM : Underperform Start Price: $20.90 ENMD Score: +119.39

Underperformed s&p since 1996 except for blip in 2000. Negative net income 2004-2007. Currently negative cash flow, ROE, ROA.

Recs

0
Member Avatar dwr53 (< 20) Submitted: 4/25/2007 8:28:15 PM : Outperform Start Price: $19.69 ENMD Score: -122.32

They have several phase two cancer candidates. Approximately 25% of the shares are owned by Celgene. I suspect they will be taken out by a big pharma looking to improve their pipeline.

Recs

0
Member Avatar jilbear (59.79) Submitted: 4/15/2007 10:50:32 AM : Underperform Start Price: $19.58 ENMD Score: +127.37

This company can only go down from the information available. They are eating cash. This is coming off their second stock offering. It will be years until any of their medications ever hit the market. The bottom line is, this company wont be profitable for at least another 3 years, and I dont think it can stick it out without exhausting its cash supply.

Recs

0
Member Avatar garupix (< 20) Submitted: 2/6/2007 1:09:14 PM : Outperform Start Price: $18.15 ENMD Score: -126.53

Antiangiogenisis is a credible approach to treating cancerous tumors and ENMD pipeline drugs are performing well in Phase II clinical trials.

Recs

3
Member Avatar hlacheen (98.88) Submitted: 12/21/2006 9:39:39 PM : Underperform Start Price: $18.59 ENMD Score: +129.61

Just look at the income statement and cash flow.... this company is a cash-burning disaster, it is NOT worth $120m

Recs

0
Member Avatar orygunian (68.38) Submitted: 12/15/2006 3:12:47 PM : Outperform Start Price: $17.93 ENMD Score: -128.05

More to follow

Recs

0
Member Avatar dfmxxxxxx (< 20) Submitted: 12/11/2006 9:53:32 PM : Outperform Start Price: $20.90 ENMD Score: -130.68

promising pipeline; finally a stream of revenue from Thalomid royalties; good management;

Recs

0
Member Avatar dorkinglad (< 20) Submitted: 10/27/2006 7:11:27 PM : Outperform Start Price: $23.10 ENMD Score: -135.67

Royalties about to kick in big-time. Several promising new drugs in the pipeline. Need for patience.

Recs

2
Member Avatar ShuntSD (96.28) Submitted: 10/20/2006 2:37:38 PM : Outperform Start Price: $22.55 ENMD Score: -136.41

As others say, a gamble with huge upside. But the small molecule research is promising and acquisition was a nice move. Keep close eye on it with stops.

Recs

0
Member Avatar quanacasee (< 20) Submitted: 10/11/2006 11:34:08 AM : Outperform Start Price: $23.87 ENMD Score: -139.24

7.00 to 9.00

Recs

0
Member Avatar toolsofignorance (70.99) Submitted: 9/25/2006 7:40:18 PM : Outperform Start Price: $18.70 ENMD Score: -138.80

worth a gamble at these prices

Recs

0
Member Avatar HiddenGems07 (54.72) Submitted: 8/25/2006 8:04:30 PM : Outperform Start Price: $19.47 ENMD Score: -143.61

Big Gamble - they may just have a drug better than Avistan. Time will tell.

Results 1 - 15 of 15

Featured Broker Partners


Advertisement